Breast cancer IHC decoder: what is your subtype
Enter ER, PR, HER2 and Ki-67 from your immunohistochemistry report to see the surrogate tumor subtype — luminal A or B, HER2-positive or triple-negative — and what it usually means for treatment.
If ER and PR are given as a score (Allred, H-score), use the percentage of stained cells — it is usually in the report too. A negative result is 0%.
Tumor subtype
Enter ER, PR and HER2 from your IHC report — your surrogate subtype and what it usually means for treatment will appear here.
The IHC subtype is a guide. The treatment plan also depends on stage, lymph nodes, grade, age and inherited mutations.
Discuss the treatment plan with an oncologistWhy the subtype matters
Breast cancer is several different diseases. Immunohistochemistry shows what drives the tumor's growth: hormones (ER and PR receptors), the HER2 protein, or neither. Ki-67 adds how actively the cells divide. These four values give the surrogate subtype — ‘surrogate’ because it is based on IHC rather than a genetic test of the tumor.
The subtype decides which drug groups can work at all: hormone therapy, anti-HER2 drugs, chemotherapy, immunotherapy. That is why, together with the stage, it is one of the main pillars of the treatment plan.
Common questions
Can the subtype differ between the biopsy and surgery?
Yes, sometimes. A tumor isn't uniform and a biopsy contains only a few cores. If values differ noticeably, the doctor decides which to rely on; when in doubt, a pathology review helps.
What if Ki-67 isn't reported?
The subtype can be worked out only partly: without Ki-67, hormone receptor-positive HER2-negative cancer can't be reliably split into luminal A and B. Ask whether Ki-67 can be added on the same slides or blocks.
Are the Ki-67 cut-offs the same everywhere?
No. This tool uses RUSSCO criteria (up to 20% low, 30% or more high, grey zone in between). Other countries and guidelines use slightly different cut-offs, and decisions always take the whole picture into account.
Sources
- Практические рекомендации по лекарственному лечению рака молочной железы — RUSSCO, 2023
- Breast Cancer HER2 Status — American Cancer Society
- ASCO and CAP Release Updated Guideline on Estrogen and Progesterone Testing in Breast Cancer — The ASCO Post, 2020
- Breast Cancer Biomarker Tests — National Cancer Institute
Other tools
- When to call your doctorFever, diarrhea, breathlessness during treatment: urgent or can it wait
- Blood count before chemoAre your neutrophils and platelets enough for the next cycle
- Chemotherapy calendarDates of cycles, blood tests and higher-risk days — export to your phone calendar
- TNM decoderWhat T, N and M mean in your report
- Tumor marker trackerA chart of CEA, CA-125, PSA and other markers for your doctor
- Second opinion checklistWhat to gather before a consultation: a list for your case
